Articles

Results from a new trial have dashed hopes that early use of two blood pressure drugs could slow the loss of kidney function caused by Type 1 diabetes.

Dr Juliana C. Chan, of the Chinese University of Hong Kong, and colleagues randomized 204 patients to structured care or to usual care. The structured care group “was managed according to a prespecified protocol with treatment goals including blood pressure

There is conflicting data over possible cancer risk from Lantus Insulin, but another alternative exists that can reduce your risk of cancer.

Diabetics undergoing total joint replacement often are at a higher risk of experiencing complications after surgery due to various pre-existing health conditions, but those complications are less likely to occur when a diabetic patient has glucose levels under control.

The FDA decision will delay the drug’s possible launch by at least two years, according to company officials.

Led by Dr. Anushka Patel, of Royal Prince Alfred Hospital in Sydney, Australia, the authors of the study examined mortality and cardiovascular risks associated with atrial fibrillation in more than 11,000 patients with Type 2 diabetes. The researchers also sought to determine whether the effects of blood pressure lowering on …

Parental precision at carbohydrate counting is associated with improved glycemic control in children with Type 1 diabetes, according to a paper in the June issue of Diabetes Care.

Being a diabetic and having just one episode of low blood sugar during a hospital stay was associated with a significantly increased risk of dying, both in the hospital and up to a year later, new research shows.

Persons with higher levels of adiponectin, a protein that is produced by fat cells and that has anti-inflammatory and insulin-sensitizing properties, have an associated lower risk of Type 2 diabetes, according to an analysis of previous studies.

Type 1 diabetes patients who start on renin-angiotensin blockers early may slow development of retinopathy by up to 70%, a clinical trial revealed. Michael Mauer, MD, of the University of Minnesota in Minneapolis, and colleagues reported that, neither an angiotensin-receptor blocker (ARB) nor an